Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Children's Mucinex is a line of over-the-counter (OTC) multi-symptom cold and cough medications specifically formulated for pediatric use, typically for children aged 4 years and older. Developed and manufactured by Reckitt Benckiser, the product line includes various formulations tailored to specific symptoms. Common active ingredients include guaifenesin, an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi; dextromethorphan HBr, a cough suppressant that acts centrally on the cough reflex center; and phenylephrine HCl, a nasal decongestant that acts as an alpha-1 adrenergic receptor agonist to reduce swelling in the nasal passages. It is indicated for the temporary relief of symptoms associated with the common cold, such as chest congestion, cough, and nasal congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Children's Mucinex.